Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Read More…
Industry, Sector and Symbol
Industry Computer programming, data processing, & other computer related
Sub-IndustryN/A
SectorBusiness Services
Phone888-798-5802
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150.68 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
Cardlytics (NASDAQ:CDLX) Frequently Asked Questions
What is Cardlytics' stock symbol?
Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."
How were Cardlytics' earnings last quarter?
Cardlytics Inc (NASDAQ:CDLX) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.30) EPS for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.31. The business had revenue of $35.99 million for the quarter, compared to analyst estimates of $36.11 million. Cardlytics had a negative net margin of 25.53% and a negative return on equity of 84.02%. The business's revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.35) earnings per share. View Cardlytics' Earnings History.
When is Cardlytics' next earnings date?
What price target have analysts set for CDLX?
6 analysts have issued twelve-month price targets for Cardlytics' shares. Their predictions range from $15.00 to $26.00. On average, they anticipate Cardlytics' share price to reach $22.8333 in the next twelve months. This suggests that the stock has a possible downside of 4.3%. View Analyst Price Targets for Cardlytics.
What is the consensus analysts' recommendation for Cardlytics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardlytics.
What are Wall Street analysts saying about Cardlytics stock?
Here are some recent quotes from research analysts about Cardlytics stock:
- 1. SunTrust Banks, Inc. analysts commented, "We hosted Cardlytics’ CEO and Co-Founder, Scott Grimes, and COO and Co- Founder, Lynne Laube, at our 6th annual internet and digital media conference for a fireside chat." (5/21/2019)
- 2. According to Zacks Investment Research, "Cardlytics, Inc. is engaged in developing a purchase intelligence platform. The purchase data includes debit, credit and bill pay data from online and in-store transactions. It helps the marketers identify, reach and influence likely buyers at scale, and measure the impact of marketing spends. The Company also operates an advertising channel, Cardlytics Direct. Cardlytics Direct delivers tailored marketing for marketers and financial institutions. Cardlytics, Inc. is based in ATLANTA, United States. " (5/16/2019)
Has Cardlytics been receiving favorable news coverage?
News articles about CDLX stock have been trending neutral this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cardlytics earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Cardlytics.
Are investors shorting Cardlytics?
Cardlytics saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 3,149,200 shares, an increase of 5.5% from the April 15th total of 2,985,400 shares. Based on an average trading volume of 210,000 shares, the short-interest ratio is currently 15.0 days. Approximately 17.8% of the company's shares are short sold. View Cardlytics' Current Options Chain.
Who are some of Cardlytics' key competitors?
Some companies that are related to Cardlytics include Eventbrite (EB), Qutoutiao (QTT), Internet Initiative Japan (IIJI), 21Vianet Group (VNET), HealthStream (HSTM), Jianpu Technology (JT), Model N (MODN), Aurora Mobile (JG), TrueCar (TRUE), The Rubicon Project (RUBI), Pintec Technology (PT), Internap (INAP), Synacor (SYNC), Sify Technologies (SIFY) and Autoweb (AUTO).
What other stocks do shareholders of Cardlytics own?
Who are Cardlytics' key executives?
Cardlytics' management team includes the folowing people:
- Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)
- Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)
- Mr. David Evans, CFO & Head of Corp. Devel.
- Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)
- Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54)
When did Cardlytics IPO?
(CDLX) raised $76 million in an initial public offering on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.
Who are Cardlytics' major shareholders?
Cardlytics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.55%), Frontier Capital Management Co. LLC (7.23%), Canaan Partners VIII LLC (7.17%), Jennison Associates LLC (5.54%), Penn Capital Management Co. Inc. (0.84%) and Penn Capital Management Co. Inc. (0.84%). Company insiders that own Cardlytics stock include Bryce Youngren, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Polaris Venture Management Co and Scott D Grimes. View Institutional Ownership Trends for Cardlytics.
Which institutional investors are selling Cardlytics stock?
CDLX stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners VIII LLC, Edmond DE Rothschild Holding S.A. and Jennison Associates LLC. Company insiders that have sold Cardlytics company stock in the last year include Bryce Youngren, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Polaris Venture Management Co and Scott D Grimes. View Insider Buying and Selling for Cardlytics.
Which institutional investors are buying Cardlytics stock?
CDLX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Tygh Capital Management Inc., FMR LLC, Penn Capital Management Co. Inc., Penn Capital Management Co. Inc., Marshall Wace LLP, Gamco Investors INC. ET AL and Teton Advisors Inc.. Company insiders that have bought Cardlytics stock in the last two years include David Thomas Evans and Scott D Grimes. View Insider Buying and Selling for Cardlytics.
How do I buy shares of Cardlytics?
Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardlytics' stock price today?
One share of CDLX stock can currently be purchased for approximately $23.87.
How big of a company is Cardlytics?
Cardlytics has a market capitalization of $538.75 million and generates $150.68 million in revenue each year. The company earns $-53,040,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. View Additional Information About Cardlytics.
What is Cardlytics' official website?
How can I contact Cardlytics?
Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]
MarketBeat Community Rating for Cardlytics (NASDAQ CDLX)
MarketBeat's community ratings are surveys of what our community members think about Cardlytics and other stocks. Vote "Outperform" if you believe CDLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
